NKGen Biotech, Inc.’s Post

NK therapy #NKGen [Nasdaq: NKGN] has successfully dosed the first patient in Phase 2 of our Phase 1/2a #Alzheimer’s trial. Additionally, early interim results from the #Phase 1 cohort of this trial are showing promising potential for NK cell therapy, #troculeucel (SNK01).

CAR-T in lymphoma continues to impress, with J&J reporting excellent results from interim analysis of their phase 3 trial for Carvykti. Patients demonstrated significant survival improvement in overall survival from a single infusion of the product. This data support the FDA decision to allow use as a secondary treatment (if patients fail their initial treatment course). Autologous cell therapies remain frustratingly out of reach for many patients due to logistical hurdles and high price tags, but their promise is being fulfilled even in their first generation of products. https://lnkd.in/gJ8jJu3C

“In 2022, the U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel (liso-cel) as a second-line treatment for patients with diffuse large B-cell lymphoma (DLBCL). However, the cost effectiveness of liso-cel is currently a topic of debate among oncologists —especially considering the drug’s cost increased from $410,300 to $447,227 between 2022 and 2023.” “This study is the first to analyze liso-cel's cost-effectiveness as a second-line therapy. A key finding underlines the importance of incorporating productivity losses into such analyses to capture the broader societal values of novel therapies. The study reveals that although these therapies offer substantial clinical benefits, their high acquisition costs and limited long-term data critically challenge their economic sustainability.” https://lnkd.in/dxHZ5KET

ImmPACT Bio’s cell therapy secures FDA approval for multiple sclerosis trial ImmPACT Bio CEO Sumant Ramachandra, M.D., Ph.D. said: “IND clearance for our bispecific CAR T-cell therapy in MS marks an exciting achievement that further expands the clinical development of our autoimmune programme. As an intended one-time treatment, IMPT-514 has the potential to reset the immune system by depleting a broad range of autoreactive immune cells implicated in the pathogenesis of MS in patients. We expect to dose the first patient in the first half of 2025.” - https://lnkd.in/dbD6NcgR #clinicaltrials #celltherapy #multiplesclerosis

The #FDA has granted accelerated approval to #Brukinsa (#zanubrutinib) in combination with #obinutuzumab for treating relapsed or refractory #follicularlymphoma. This marks the first approval of a BTK inhibitor for this condition, offering new hope to patients after unsuccessful systemic therapies. “This accelerated approval of Brukinsa represents an important advancement, offering the first and only BTK inhibitor treatment for follicular #lymphoma patients in the US who have either not responded to initial therapies or have experienced relapse. Brukinsa is the only BTK inhibitor to date that shows efficacy with this type of malignancy and now has the broadest label, including five oncology indications, of any medication in its class globally,” said Dr. Mehrdad Mobasher, Chief Medical Officer, #Hematology at BeiGene. https://lnkd.in/dDU83i_8

Just in ESMO - European Society for Medical Oncology open extended follow up nivolumab plus Cabozantinib ✅Median PFS was improved with NIVO + CABO versus SUN [16.6 versus 8.4 months; ✅ Median OS (95% CI) in ITT patients: 49.5 months (40.3 months-NE) with NIVO + CABO vs 35.5 months (29.2-42.3 months) with SUN. https://lnkd.in/d3nuHPER

Today, at the AACR 2024 Annual Meeting, Nurix’s Chief Scientific Officer, Gwenn Hansen, Ph.D., discussed Nurix’s novel, brain penetrant, BTK degrader NX-5948 and presented the first data demonstrating clinical activity of a targeted protein degrader in the brain.     NX-5948 has the potential to address significant unmet medical need in CNS lymphoma and certain CNS-focused autoimmune diseases such as multiple sclerosis.      Learn more here:  https://bit.ly/3vL7csN

🚨 FDA approves Daratumumab plus Vrd for newly diagnosed Multiple Myeloma patients 🚨 The U.S. Food and Drug Administration (FDA) approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro; Janssen Research and Development, LLC) on July 30 2024. This approval is for use in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for induction and consolidation treatment in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant. The approval was based on the results of the PHASE 3 PERSEUS trial, an open-label, randomized, active-controlled study comparing the two regimens. The trial included patients aged 70 years and younger, with a total enrollment of 709 patients. #oncology #hematologicmalignancies

Operationalizing Bispecific Antibodies Across Academic and Community Oncology Centers in Hematologic Malignancies: An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care. #finance #pharmacy #lifesciences